| Identification | Back Directory | [Name]
DPM-1001 | [CAS]
1471172-27-6 | [Synonyms]
DPM-1001
DPM-1001
(DPM1001)
Cholan-24-oic acid, 7-hydroxy-3-[[4-[(2-pyridinylmethyl)amino]butyl]amino]-, methyl ester, (3α,5α,7α)- | [Molecular Formula]
C35H57N3O3 | [MDL Number]
MFCD32201053 | [MOL File]
1471172-27-6.mol | [Molecular Weight]
567.86 |
| Chemical Properties | Back Directory | [Boiling point ]
656.4±50.0 °C(Predicted) | [density ]
1.10±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
14.83±0.70(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property[1]. | [in vivo]
DPM-1001 (oral or intraperitoneal administration; 5 mg/kg; once daily; 50 days) inhibits diet-induced obesity in mice by improving insulin and leptin signaling. DPM-1001-treated, high-fat diet-fed mice starts losing weight within 5 days of treatment. The weight loss continues for approximately 3 weeks, after which no further decrease in body weight is observed[1]. | Animal Model: | 18 weeks of age, high-fat diet (HFD)-fed obese male mice (C57bl6/J)[1] | | Dosage: | 5 mg/kg | | Administration: | Oral or intraperitoneal administration; 5 mg/kg; once daily; 50 days | | Result: | Led to an 5% decrease in body weight.Improved glucose tolerance and insulin sensitivity in glucose tolerance and insulin tolerance in vivo. |
| [References]
[1] Krishnan N, et al. A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. J Biol Chem. 2018 Feb 2;293(5):1517-1525. DOI:10.1074/jbc.C117.819110 |
|
|